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The thymus of irradiated  animals can be repopulated by the progeny of precursors 
from hemopoietic  tissues  (1-5). 1 Although  the  existence  of these  functional  prothy- 
mocytes has long been recognized, only modest progress has been made in identifying 
and  isolating them.  In the  mouse,  functional  thymocyte progenitors  are part  of the 
"null" (non-T, non-B) cell compartment of bone marrow and spleen, and enrichments 
of 10- to 30-fold, respectively,  have been obtained  through depletion  procedures  in 
conjunction  with  density  gradient  centrifugation  (6).  Partial  separation  of prothy- 
mocytes and  pluripotent  hemopoietic stem  cells  (CFU-S) 2 has  been  observed  using 
density gradient centrifugation or velocity sedimentation  (7,  8). 
The mouse bone marrow cell fractions that are enriched in prothymocyte activity 
have been found to be comparably enriched in terminal deoxynucleotidyl transferase 
(TdT)  activity  (6).  Moreover, TdT-positive  cells have been shown to express T  cell 
surface  antigens  after  brief in  vitro  induction  with  thymosin  (9)  and  thymopoietin 
(10).  Hence,  they have been postulated  to be the most likely candidates  for prothy- 
mocytes in bone marrow. 
Prothymocyte  activity  has  also  been  found  in  adult  spleen,  which  lacks  TdT- 
positive cells  (5); 1 and  some TdT-negative  cells  in bone marrow and  spleen  can  be 
induced to express T  cell differentiation  antigens  (9).  This has prompted the specu- 
lation that at least two subsets of prothymocytes exist in the mouse. 
In the rat, unlike the mouse, the Thy-1.1 antigen is readily detectable on a  variety 
of immature lymphohemopoietic cells in bone marrow, spleen, and fetal liver (11-14). 
By using  multiple  parameter  analysis  of relative  cell  size  (low-angle  light  scatter), 
relative  fluorescence intensity for Thy-1 antigen,  and relative  sensitivity to cortisone 
to resolve subsets  of rat  bone  marrow cells  on the  fluorescence-activated  cell  sorter 
(FACS), we have developed protocols for separating  and  markedly enriching pluri- 
* Supported by grants AI09649 and  AI14743 from the  National Institute  of Allergy and  Infectious 
Diseases, U. S. Public Health Service, and by grant CH 111 from the American Cancer Society. 
1Greiner, D.  L., I. Goldschneider, and  D.  M.  Lubaroff. Identification of thymocyte progenitors in 
hemopoietic tissues of the rat.  I. A quantitative  assay system for thymocyte regeneration. Manuscript 
submitted for publication. 
2 Abbreviations used in this paper."  ART, antigen of the rat thymus; CFU-S, in vivo spleen colony-forming 
unit; FACS, fluorescence-activated  cell sorter; TdT, terminal deoxynucleotidyl transferase. 
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potent hemopoietic stem cells, myeloid proeenitor cells, and TdT-positive cells (15, 
16).  We  have  also  developed  a  thymocytt  regeneration assay  system  to  quantify 
relative prothymocyte activities in cell suspensions ti'om rat bone marrow and spleen) 
This assay uses antiserum to the antigen of the rat thymus (ART-1  a and ART-1  b) T 
cell alloantigens to directly identify donor- and host-origin thymocytes in histocom- 
patible adoptive hosts. 
In the present study, we adapted these procedures to isolate functional prothymo- 
cytes  on  the  FACS.  The  results  indicate  that  two  subsets  of  prothymocytes  are 
represented in rat bone marrow and spleen, as distinguished by their relative sensitiv- 
ities  to  dexamethasone.  The  prothymocytes in untreated bone marrow  have  been 
enriched approximately 110-fold; and the prothymocytes in dexamethasone-treated 
bone marrow have been enriched approximately 260-fold. 
Materials and Methods 
Animals.  Rats of the LEW, NBR, BUF, and M520 inbred strains were obtained from the 
Mammalian Genetics  and  Animal  Production  Section  of  the  National  Cancer  Institute, 
Frederick, MD. Rats used in these experiments were 4-6 wk old, housed two to three per cage, 
and fed  commercial rat  chow and acidified, chlorinated water  (pH  2.2;  free  chlorine, 5-10 
ppm) ad lib. 
Antisera.  Antisera to the A.R.T.-1  ~ and A.R.T.-1  b alloantigens were produced, as previously 
described, by appropriate reciprocal immunizations and absorptions so as to be functionally 
specific by indirect immunofluorescence. In some experiments, a monoclonal antibody to the 
A.R.T.-lg  a alloantigen (termed  BC84A)  was  used  and was  the  kind gift  of Dr. John  Ely, 
University of Chicago, Chicago, IL. An F(ab')2 fragment of rabbit IgG anti-rat Thy-l.1 was 
prepared, and its specificity was determined as before (14, 17). 
Immunofluorescence.  Single-cell suspensions were prepared in RPMI  1640 tissue culture me- 
dium as previously described. Bone marrow and spleen cell suspensions were routinely depleted 
of erythrocytes by treatment with 0.168 M NH4C1 before staining for immunofluoresenee (15). 
A.R.T.-1- and Thy-l-labeled cell suspensions were developed for indirect surface immunoflu- 
orescence by incubation with an F(ab')2 fragment of an IgG fraction of fluorescein-conjugated 
rabbit anti-rat or goat anti-rabbit IgG, respectively (N. L. Cappel Laboratories, Cochranville, 
PA). 
Double immunofluorescence for Thy-1 and TdT was performed as  follows:  bone marrow 
cells were  incubated with monoclonal OX7  antibodies to Thy-l.1  (Accurate Chemical and 
Scientific Corporation, Westbury, NY)  and developed for surface immunofluorescence with 
rhodamine-conjugated goat anti-mouse IgG that  had been passed over a  normal rat  serum 
Sepharose 4B affinity column to remove cross-reacting antibodies. The stained cell suspensions 
were analyzed and sorted on the FACS, smeared onto glass slides using a cytocentrifuge, and 
fixed in cold absolute methanol for 20 min. The cell smears were then reacted with an affinity- 
purified IgG fraction of rabbit anti-TdT (18, 19)  that was the kind gift of Dr. F. J.  Bollum, 
Uniformed Services,  University of the  Health  Services,  Bethesda,  MD.  The  smears  were 
developed for intranuclear immunofluoresence with a fluorescein-conjugated goat anti-rabbit 
IgG. Doubly labeled cells were counted using a  Zeiss Universal Microscope (Carl Zeiss Inc., 
New York) equipped with narrow band filters for rhodamine and fluorescein. 
Cell Sorting.  Bone marrow cells were analyzed and sorted on a  fluorescence-activated cell 
sorter (FACS IV, B-D FACS Systems,  Becton, Dickinson & Co., Sunnyvale, CA) according to 
low angle light scatter and relative fluorescence intensity for Thy-1.1, as shown in Figs.  1 and 
2  (15, 16). Sorted  cells  were  collected  in RPMI  medium supplemented with  10%  gamma 
globulin-free horse serum. 
Irradiation.  Recipients received 750 rad total body irradiation from a I~7Cs source (Gamma 
Cell 40 Irradiator, Atomic Energy of Canada, Ltd., Ottowa, Canada; ~ 120 rad/min) 2-6 h 
before receiving bone marrow cells. 
In Vivo CFU-S.  The in vivo spleen colony-forming  activity of rat bone marrow and spleen 
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FIc.  l.  Relative size distribution of nucleated rat bone marrow cells as determined by low-angle 
light scatter on the FACS. The various fractions tested for prothymocyte activity are designated by 
Roman numerals and capital letters.  Erythrocytes,  which normally present as peak I to the left of 
the nucleated cells, have been lysed with 0.168 M NH4CI. 
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Fie;.  2.  Relative size distribution of the upper 10th percentile of Thy-l-positive bone marrow cells 
(  .....  )  superimposed on relative  size distribution of total  nucleated bone marrow cells  (--)  from 
untreated (A) and dexamethasone-treated (B) rats, as determined by low angle light scatter on the 
FACS. 
4-5 wk-old recipients. Spleen colonies were enumerated 11  d  later (15). 
Thymocyte Regeneration Assay.  The quantitative thymocyte regeneration assay using histocom- 
patible, A.R.T.-1-disparate rat strain combinations has been previously described in detail, and 
was used throughout these studies. Donor-recipient strain combinations for individual experi- 
ments are reported in the text. Aliquots of thymocytes in the recipient were routinely stained 
with the A.R.T.-1 a and A.R.T.-l  b antisera, permitting >95% of the thymocytes to be identified 
as being of host or donor origin. In each individual experiment, a  linear dose-response curve 
was generated to eliminate interexperimental variations in calculating the relative contents of 
prothymocytes in the cell populations separated on the FACS. The observed enrichments were 
determined by comparing the number of fractionated and unfractionated bone marrow cells 
required to produce an equivalent degree of thymocyte regeneration as determined from the 
linear dose-response curve. To assure such linear responses, the number of fractionated bone 
marrow cells injected was adjusted in each instance to approximate the prothymocyte activity 
contained in 5-15 ×  10  ~ unfractionated bone marrow cells. 
In bone marrow from normal rats, the predicted enrichment ofprothymocytes  was calculated 
as the reciprocal of the percentage of total nucleated bone marrow cells present in each fraction. D.  L.  GREINER,  I.  GOLDSCHNEIDER,  AND  R.  W.  BARTON  1451 
In bone marrow from dexamethasone-treated rats, the predicted enrichment of prothymocytes 
was similarly calculated and corrected for the depletion of dexamethasone-sensitive cells in the 
starting (unfractionated)  cell suspension (40% depletion =  1.6-fold enrichment; see Table II). 
Dexamethasone Treatment.  Donor rats were injected interperitoneally with 0.5 mg dexameth- 
asone per  100 g body weight  72 h  before bone marrow or spleen cells were harvested. 
Opsonization of Bone Marrow  and  Spleen  Cells.  Donor  cells  were  sensitized  with  anti-Thy-1 
antibodies, as described previously (14,  15). Briefly,  1 ×  106 nucleated cells were incubated for 
20 min at 4°C with  10 p.l monoclonal OX7  anti-Thy-1  antibodies  (IgG;  1:400  dilution).  The 
cells were washed twice, checked for viability by trypan blue exclusion, and diluted for injection. 
The  presence  of mouse  immunoglobulin  on  the  treated  rat  cells  was  verified  by  indirect 
immunofluorescence. 
Results 
Sensitivity of Prothymocytes to Dexamethasone.  The thymocyte regenerating capacities 
of 50 ×  106 normal and dexamethasone-treated M520 strain bone marrow and spleen 
cells were determined  15  and  16 d, respectively, after injection  into irradiated  (750 
rad)  BUF recipients. There was no significant difference between the percentage or 
absolute numbers of donor-origin (ART-1 a) thymocytes that were generated by bone 
marrow cells from untreated  or dexamethasone-treated rats  (Table I). However, 50 
X  106 untreated spleen cells generated significantly greater percentages and numbers 
of donor-origin thymocytes than did 50 X  106 dexamethasone-treated spleen cells. 
The thymocyte regenerative capacity of normal  vs.  dexamethasone-treated  bone 
marrow cells was equivalent at all time points studied up to 140 d after transfer (Fig. 
3, P >  0.8). In both cases, the percentage of donor-origin thymocytes increased linearly 
between  days  14  and  22  (r  2 --  0.973),  as  previously reported. 1 A  high  correlation 
coefficient was observed (r =  0.986)  when these linear increases in the percentages of 
donor-origin  thymocytes  were  compared.  The  long-term  stability  of  the  thymic 
chimeras induced by injection of normal or dexamethasone-treated bone marrow was 
also equivalent (81.5% vs. 81.2%). Thus, on a per cell basis, the thymocyte progenitor 
TABLE  I 
Effect of Dexamethasone on Prothymocytes in Rat Bone Marrow and Spleen * 
Cell source 
Dexameth- 
asone 
treatment:~ 
Bone marrow  No 
Yes 
Donor-origin thymocytes 
(ART-I a) 
Host-origin thymocytes 
(ART- 1  b  ) 
Number/  Number/ 
Percentage  thymus§  Percentage  thymus§ 
(x  10  -6)  (x  10  -6) 
23.6  52 +  16  75.5  168 ±  51 
28.7  50 ±  11  70.9  124 +  28 
Spleen  No  9.7 -  4.0  22.9 +  9.8  89.0 +  3.8  221  +  80 
Yes  3.9 +  2.211  9.1 +  7.21[  95.5  +  2.21  210 +  73 
* BUF recipients (4 to 6/group), irradiated with 750 rad (bone marrow recipients) or 600 rad (spleen cell 
recipients), were analyzed on the FACS for the presence of donor- and host-origin thymocytes 15 d after 
transfer of 50 ×  106 M520 bone marrow cells and 16 d after transfer of 50 X  l06 M520 spleen ceils. 
:~ Donor  rats  were  injected  intraperitoneally with 0.5  mg dexamethasone  72  h  before harvest  of bone 
marrow or spleen cells. 
§ Mean +  SD. 
[[ Significantly different from untreated controls (P <  0.001). 1452  IDENTIFICATION  OF  THYMOCYTE  PROGENITORS 
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Ftc.  3.  Generative kinetics of donor-origin thymocytes in irradiated  (750 rad)  BUF recipients (3- 
4  per  group)  injected  with  50  ×  106  normal  (open bars)  or dexamethasone-treated  (closed  bars) 
M520  bone marrow cells,  as determined  by analysis on the FACS.  A  linear increase with  time  is 
seen between  days  14  and  22  in  the percentage  of donor-origin  thymocytes in  recipients  of both 
normal  (r  2 =  0.974)  and dexamethasone-treated  (r  2 =  0.973)  bone marrow (correlation coefficient 
r =  0.986). There were no significant differences (P >  0.8) observed at any point over a  140-d period 
between the thymocyte generative capacities of equal numbers of normal or dexamethasone-treated 
bone marrow cells. 
TABLE  II 
Effects of Dexamethasone on Rat Bone Marrow and Spleen Cells * 
Dexametha-  Nucleated cells 
Cell source  sone treat-  per femur or  Thy-l-positive  TdT-positive  CFU-S/106 
cells$  cells:~  cells§  ment  spleen (×  10  -s) 
%  % 
Bone marrow  No  156 +  21  36.8 +  3.5  5.7 +  0.7  23 +  5 
Yes  98 +  811  14.1  +_ 3.711  0.9 +  0.311  44 +  81[ 
Spleen  No  374 +  30  12.5  _+  1.1  <0.1  8 +  1 
Yes  144 +  1911  6.6 +  1.all  <0.1  21  +  3II 
* Analysis of 4-6 spleens and femurs from untreated or dexamethasone-treated  M520 rats (mean _+ SD). 
Determined by indirect immunofluorescence. 
§ Spleen colonies were enumerated  11  d  after injection  of 1 ×  106 nucleated  bone marrow or spleen cells 
into syngeneic recipients irradiated  with 750 rad. 
11 Significantly different  from untreated controls (P <  0.001). 
activity in normal and dexamethasone-treated rat bone marrow was the same. 
These  results contrasted with  the effects of dexamethasone  on  other cell types in 
bone marrow  and spleen. As shown  in Table II, dexamethasone treatment  caused a 
significant  decrease  in  the  total  numbers  of nucleated  cells in  bone  marrow  (40%, 
P  <  0.001)  and spleen (65%, P  <  0.001).  As reported previously (15), the decrease in 
bone marrow cells was almost entirely accounted for by a  decrease in Thy-l-positive 
lymphoid cells, including a  marked  decrease in TdT-positive cells. The  decrease in 
spleen  cells  was  due  primarily  to  a  decrease  in  Thy-l-negative  lymphoid  cells. 
Conversely, CFU-S, which are cortisone-resistant (15), were proportionately enriched 
in bone marrow and spleen after treatment with dexamethasone. Had all prothymo- 
cytes been  dexamethasone-resistant, comparable enrichments  should  have  been  ob- 
served. The fact that no enrichment of prothymocytes occurred in bone marrow after 
dexamethasone treatment, and a  decrease occurred in spleen, suggests that  ~40% of 
prothymocytes in bone marrow and ~80% of prothymocytes in spleen are dexameth- 
asone sensitive. D.  L. GREINER, I. GOLDSCHNEIDER,  AND  R.  W.  BARTON  1453 
Light Scatter Profile of Prothymocytes.  Normal rat  bone marrow cells were separated 
into  various  fractions  according to  the  low  angle  light  scatter  profile  (relative  size 
distribution)  observed on the FACS (Fig.  1). As previously described,  peak I  consists 
of erythrocytes,  peak  II contains  mainly  lymphocytes and  some  erythroblasts,  and 
peak III contains undifferentiated blast cells and cells of the myeloid series (15). Most 
CFU-S activity is  present  in the left  side of peak III (fraction IIIL), and most TdT- 
positive cells are present in the valley between peaks II and III (fraction B)  (15,  16). 
Results  in  Table  III  show  the  relative  size  distribution  profile  of presumptive 
prothymocytes. No prothymocyte activity was detectable  in  peak II; ~25%  of total 
prothymocyte activity  was  present  in  fraction  B;  and  ~75%  of the  prothymocyte 
activity was  present  in  fraction C.  Further  analysis  showed  that  ~75%  of the  total 
thymocyte regenerating activity was present  in fraction IIIL. Therefore, by process of 
exclusion,  ~50%  of the  total  prothymocyte activity  was  located  in  that  portion  of 
fraction IIIL that was to the right of fraction B; and 25% of the prothymocyte activity 
was in fraction IIIa. 
Opsonization of Prothymocytes with Anti-Thy-1  Antibodies.  Results  in  Table  IV show 
that all thymocyte regenerating activity was abrogated by treating M520 donor strain 
rat spleen or bone marrow cells with monoclonal IgG anti-Thy-1.1  antibodies imme- 
diately  before  injection  into  irradiated  BUF  strain  recipients.  As  anticipated  (15), 
CFU-S  activity was also eliminated  by this  procedure.  These results  suggested  that 
prothymocytes, like CFU-S and other immature hemopoietic cell types in the rat, are 
Thy-1  positive.  Direct  evidence for this  contention was provided  by FACS analysis 
(see below). 
Fluorescence Distribution Profile of Prothymocytes.  The thymocyte regenerating activity 
of rat  bone  marrow cells  that  had  been  treated  with  an  F(ab')2  fragment  of rabbit 
anti-rat-Thy-l.1  and developed for immunofluorescence with an F(ab')2 fragment of 
fluorescein-conjugated goat anti-rabbit  IgG was only slightly less than  that of unla- 
beled bone marrow cells  (Table V, line  10).  Moreover, passage of bone marrow cells 
through the FACS did not significantly affect their thymocyte regenerative potential. 
Hence, it was possible to sort rat  bone marrow cells on the FACS according to their 
TABLE III 
Distribution of Prothymocytes in Rat Bone Marrow According to Relative Low Angle 
Light Scatter 
Fraction* 
Percentage of total  Observed  Expected 
nucleated bone  enrichment of  enrichment of 
marrow cells per  prothymocytes:~  prothymocytes 
fraction 
B  20.1  1.0  5.0 
C  39.5  2.3  2.5 
II  42.3  < 1.0  2.4 
III  57.7  1.6  1.7 
IIIL  25.9  4.7  3.9 
IIIa  26.2  1.0  3.8 
* Bone marrow cells were fractionated on the FACS, as described in Fig. 1. 
Calculated as described in Materials and Methods. Donor-recipient combinations 
included M520 into BUF and NBR into LEW strain rats. The percentages of  donor- 
and host-origin thymocytes were determined 16-20 d after transfer of bone marrow 
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TABLE  IV 
Effect of Anti-Thy-1  Serum on Prothymocytes and CFUoS in Rat Bone Marrow and Spleen* 
Cell source  Treatment  CFU-S/106 
cells 
Donor-origin  thymocytes  Host-origin thymocytes 
Number/  Number/ 
Percentage  thymus  Percentage  thymus 
(X  10 -6 )  (X  10 -6 ) 
Bone  Medium  22.4 +_ 6.0  42.1  +  13.7  70.7 +__ 36.4  56.0 +--  14.0  94.6 -- 41.6 
Marrow  Anti-Thy-l.1  0  <1.0  <1.0  96.8 +  0.4  67.0 +  76.0 
Spleen  Medium  11.5 "+- 2.1  10.4  13.7  82.2  113 
Anti-Thy- 1.1  0  <  1.0  <  1.0  95.3  137 
* Anti-Thy-l.1  (OX7) or medium-treated M520 spleen  and bone marrow cells were injected  into 750 rad- 
irradiated  BUF recipients  (3  4/group). Spleen colonies were counted 11 d after injection  of 106 nucleated 
cells. The percentage  of donor-  and host-origin  thymocytes in aliquots of thymus cells  from  individual 
bone marrow recipients  or pools of thymocytes from spleen cell recipients  was determined by fluorescence 
analysis on the FACS 16 d after transfer of 50 ×  106 nucleated cells. Results are expressed  as mean +  SD. 
TABLE  V 
Distribution  of Prothymocyles in Rat Bone Marrow According to Relative Fluorescence Intensity for Thy-1 
Antigen 
Untreated bone marrow ceils  Dexamethasone-treated  bone marrow cells 
Thy- l-positive cells  Percentage of  Observed  Predicted  Observed 
Percentage  of total nu-  Predicted  (percentile)*  total nu-  enrichment  enrichment  enrichment 
cleated bone  cleated bone marrow  enrichment of 
of prothy-  of prothy-  of prothy-  prothvmocvtesl ] 
.........  lls  naocytes][  ....  'tes][  cells per fraction  mocv es]l  "  " 
per fraction  '  ' 
91-100 
(fraction IIIL)~  1.1  112  90  0.35 (0.22)¶  260  286 (458)¶ 
91  100  4.5  21  22  21  (I.3)  45  48 (77) 
1 90  40.8  <1  2.5  21.0 (13.2)  <1  4.8 (7.7) 
Thy  l  plus 1-90  96.5  <I  1  97.7 (61.3)  <1  1.0 (16) 
76  100  11.1  6.3  9  ND**  ND  ND 
76  90  ND  ND  ND  3.3 (2.1)  <1  30 (48) 
1  75  33.2  <1  3  16.6  (10.4)  <1  6 (9.6) 
Thy-I  plus  1  75  87.5  <1  1.1  93.2 (58,4)  <1  1.1  (1 8) 
Thy- 1 negative  56.2  -( 1  1,8  78.0 (48.3)  <;1  1.3 (2. I ) 
Unseparated§  100.0  l  1  100,0  (62.7)  09  1.0 (1.6) 
*  Percentiles of Thy-l-positive cells were separated  on the FACS according to relative fluorescence intensity (see  rcf.  16 for details),  Results 
represent  means of 2  4 experiments. 
:~ Upper  10th percentile of Thy-l-positlve cells in fractions IIIL (Figs. 1 and 2). 
§ Comparable results were obtained with unlabeled, unsorted bone marrow cells and with anti Thy- l-labeled, FACS sorted (but unseparated) 
bone marrow cells. 
11 Calculated as described in Materials and Methods. Values of<l  indicate that  no prothymocytes were detected. 
¶ Values in parentheses are corrected  for depletion of dexamethasone-sensitive  cells in starting (unfractionated)  cell suspension 
** Not determined. 
relative  fluorescence  intensity  for  the  Thy-l.1  antigen  and  to  assess  the  thymocyte 
regenerating  capacities  of the various  cell  fractions. 
Results  in Table V  show that  all prothymocyte  activity in normal rat  bone marrow 
resides  in  the  upper  10th  percentile  of  Thy-l-positive  cells,  as  judged  by  relative 
fluorescence  intensity.  Separation  of this  fraction,  which  represented  ~4.5%  of total 
nucleated  bone  marrow  cells,  was  accompanied  by  a  21-fold  enrichment  of prothy- 
mocyte  activity,  as  predicted.  No  prothymocyte  activity  was  found  in  the  Thy-1- D. L. GREINER, I. GOLDSCHNEIDER, AND R. W.  BARTON  1455 
negative cell fraction or in the lower 90th percentile of Thy-l-positive cells. 
Combining the results obtained from light scatter analysis (Table III) with results 
based on Thy-1 fluorescence intensity (Table V), the predicted enrichment of prothy- 
mocytes in the upper  10th percentile of Thy-l-positive cells in fraction IIIL (Figs.  1 
and 2), representing  1.1% of total nucleated bone marrow cells, was approximately 
90-fold. The observed enrichment in this cell fraction was  112-fold (Table V, line 1). 
Much  greater  enrichment  of prothymocyte  activity  was  obtained  when  bone 
marrow cells from dexamethasone-treated donors were sorted according to the relative 
intensity of Thy-1 fluorescence (Table V). Separation of the upper 10th percentile of 
total Thy-l-positive cells, representing ~2.1% of dexarnethasone-resistant bone mar- 
row cells, resulted in a  45-fold enrichment of prothymocyte activity; and separation 
of the upper  10th percentile of Thy-l-positive cells in  fraction IIIL (Figs.  1 and  2), 
representing  0.35%  of total  dexamethasone-resistant  cells,  resulted  in  a  260-fold 
enrichment of prothymocyte activity. Again,  the observed enrichments were ~40% 
lower than what would have been predicted had all prothymocytes been dexameth- 
asone-resistant. Hence, injection of as few as 2.9 ×  104 cells from the prothymocyte- 
enriched cell fractions of dexamethasone-treated bone marrow donors generated 7.3% 
(6.6  X  106) donor-origin thymocytes by  16 d  after cell transfer, whereas  7.5  ×  106 
unfractionated bone marrow cells were required to generate equivalent numbers of 
donor-origin thymocytes. 
Fluorescence Distribution  Profile of TdT-positive Cells.  The distribution of TdT-positive 
cells in bone marrow from untreated and dexamethasone-treated rats was determined 
on  the  FACS  according  to  relative  fluorescence intensity  for Thy-1  antigen.  The 
results in Table VI are comparable to those published previously (16). Thus, ~75% of 
total TdT-positive cells in untreated bone marrow were present  in the upper 25th 
percentile of Thy-l-positive cells, and >80%  of TdT-positive cells were sensitive to 
dexamethasone. 
Comparison  with  results  in  Tables V  and  VI  shows  that,  although  both  TdT- 
positive cells and  prothymocytes are each strongly Thy-1  positive, there are major 
disparities in both their distribution profiles and degrees of enrichment. Thus, in both 
untreated and dexamethasone-treated bone marrow, ~70% of total TdT-positive cells 
were present in the lower 90th percentile of Thy-l-positive cells in which no prothy- 
mocyte activity is detectable. Moreover, in the fraction in which both TdT-positive 
TABLE VI 
Distribution of TdT-Positive Cells in Rat Bone Marrow According to Relative Fluorescence  Intensity for 
Thy- 1 Antigen * 
Untreated bone marrow cells  Dexamethasone-treated  bone marrow cells 
Thy-1-positive  Observed en-  Observed en- 
cells (percen-  Percentage of total  Percent TdT-posi-  richment of  Percentage of total  Percent TdT-posi-  riehment of 
TdT-positive cells  tive cells per  TdT-positive  tile)  TdT-positive cells  rive cells per  TdT-positive  per fraction  fraction 
per fraction  fraction  cells  cells 
91  100  30.1 ±8A  17.5  ±4,3  3.1  28.4±3.6  13.5±4.5  15.0 
76-90  43.3 ±  5.5  17.9 ±  5.1  3.1  42.4 ~  12.4  13. l  ::t: 6.4  14.6 
1  75  26.6±  10.6  2,1  ±  1.3  0.4  29.2±  12.5  1.6±0.7  1.8 
Thy- 1  -negative  <0.2  <0.1  <0.1  <0.1  <70.1  <0.1 
Unseparated  100  5.7 ±  0.7  1.0  100  0.9 ±  0.3  1.0 
* Percentiles of Thy-l-po~itive cells were separated on the FACS according to relative fluorescence intensity (surface rhodamine staining), and 
methanol-fixed smears of the separated cell fractions were stained with anti-TdT antibodies (intranuclear fluorescein staining) (see Materials 
and Methods). Results represent the means ±  SD of three experiments. 1456  IDENTIFICATION  OF  THYMOCYTE  PROGENITORS 
cells and prothymocytes are present  (upper  10th  percentile of Thy-l-positive cells), 
the enrichment  of prothymocytes was much greater than that  of TdT-positive cells 
(21-fold vs. 3-fold in untreated  bone marrow;  45-fold vs.  15-fold in dexamethasone- 
treated bone marrow). 
Discussion 
The results of this study point to the existence of two subsets of prothymocytes, one 
of which  is sensitive to dexamethasone,  the  other of which  is  not.  Dexamethasone 
treatment  neither  enriched  nor depleted  bone marrow prothymocyte activity,  sug- 
gesting that the proportional distribution of these two prothymocyte subsets roughly 
approximates that of other dexamethasone-sensitive and -resistant bone marrow cells. 
Thus, it can be calculated that ~40% of prothymocytes in bone marrow and ~80% of 
prothymocytes in spleen are dexamethasone-sensitive. This interpretation  is strongly 
supported  by a  proportionate enrichment  of CFU-S  in  bone marrow and spleen of 
dexamethasone-treated  donors.  Unlike  prothymocytes,  essentially  all  CFU-S  are 
resistant to adrenal glucocorticosteroids (15). Our results are also consistent with those 
of Basch and Kadish (20), who observed only a minimum enrichment ofprothymocyte 
activity in bone marrow and spleen from hydrocortisone-treated mice. An alternative 
explanation  for  the  present  results  is  the  depletion  of a  dexamethasone-sensitive 
population of regulatory cells that influence the function of dexamethasone-resistant 
prothymocytes. However, recent mixing experiments using untreated and dexameth- 
asone-treated bone marrow cells have not provided a  basis for the existence of such 
regulatory cells (unpublished observations). 
Aside from their differential sensitivities to dexamethasone, we did not detect other 
distinguishing features between the two subsets of presumptive prothymocytes. Both 
were similar with  respect  to relative light  scatter,  relative fluorescence intensity  for 
Thy-1 antigen, and relative thymocyte regenerating capacity. Given that prothymo- 
cyte activity was assayed  72  h  after administration  of dexamethasone,  it is possible 
that  dexamethasone-sensitive prothymocytes were  generated  during  this  period  by 
dexamethasone-resistant precursors. 
The presence of high concentrations of Thy-1 antigen on functional prothymocytes 
extends the known distributions of this marker on immature lymphohemopoietic cells 
in the rat. Previous studies (11-16, 21, 22) demonstrated Thy 1 antigen on pluripotent 
hemopoietic  stem  cells,  myeloid  (and  probably  erythroid)  progenitor  cells,  TdT- 
positive  bone  marrow cells,  cortical  thymocytes, and  immature  members of the  B 
lymphocyte lineage. 
In  the  rat,  bone  marrow  precursors  of  peripheral  T  cells  have  been  enriched 
approximately four-  and  eight-fold  by sorting  on  the  FACS  according  to  relative 
fluorescence intensity for Thy-1 and W3/13 antigens, respectively (23,  24).  Although 
the  identity  of  these  precursors  is  unknown,  it  is  likely  that  they  are  actively 
proliferating cells (25).  However, there is no direct evidence that these T  lymphocyte 
regenerating ceils are prothymocytes. 
Although the quantitative thymocyte regeneration assay permits accurate compar- 
isons to be made of the relative prothymocyte contents of various cell suspensions, it 
does not allow the absolute numbers ofprothymocytes to be directly quantified) This 
is due to the long lag period  (10-19  d)  that  precedes the onset of the linear growth 
phase  of donor-origin  thymocytes and  the  absence  of information  concerning  the D.  L. GREINER, I. GOLDSCHNEIDER, AND R. W.  BARTON  1457 
seeding efficiency of prothymocytes to the thymus of the adoptive host. Nonetheless, 
an estimate of the maximum numbers of dexamethasone-resistant prothymocytes in 
the 260-fold enriched fraction can be made. Thus, using a similar protocol to isolate 
CFU-S on the FACS  (15), we determined that at least 40% of the cells in the upper 
10th  percentile  of Thy-l-positive cells  in  fractions  IIR and  IIIL (mostly  IIIL) from- 
cortisone-treated donor rats are CFU-S.  Myeloid and erythroid progenitors are not 
significantly  represented  in  this  fraction;  and  ~20%  of  the  cells  are  basophilic 
erythroblasts. Therefore, if it is assumed that the remaining 40% of the cells in this 
fraction are prothymocytes, it can be calculated  that  a  maximum of 0.15% of total 
dexamethasone-resistant  bone  marrow  cells  are  prothymocytes  (40%  ×  0.35%;  see 
Table V, line  1). A similar calculation suggests that a  maximum of 0.25% of cells in 
untreated bone marrow are prothymocytes. This value is comparable to that assigned 
to myeloid and erythroid progenitor cells (26). 
In contrast to the above estimates of the frequency of functional prothymocytes in 
rat bone marrow, it has been observed (9, 27, 28)  that between 5 and  10% of cells in 
bone marrow and spleen  from both  normal and congenitally athymic mice can be 
induced by a variety of factors to express T  cell-specific differentiation antigens. Some 
of these cells have the ability to migrate to the thymus of irradiated recipients (29). It 
has, therefore, been presumed that many, perhaps most, of these inducible cells are 
prothymocytes. If it is assumed for the purpose of argument that 5% of bone marrow 
cells are prothymocytes, then a maximum enrichment of only 20-fold is possible. Yet, 
we attained  prothymocyte enrichments of 112-fold for untreated  bone marrow and 
260-fold for dexamethasone-treated bone marrow, with recoveries of ~75%  in  each 
instance. Three likely explanations for this discrepancy are evident: (a) most inducible 
prethymic cells do not  function  as  prothymocytes  (i.e.,  they can not  migrate to or 
significantly proliferate in the thymus);  (b)  the adoptive transfer system only detects 
a minor subset of prothymocytes; (c) the thymocyte generative activity in our assay is 
due to pluripotent hemopoietic stem cells (CFU-S). There is no reason to believe that 
the difference between the percentage of inducible prethymic cells in the mouse and 
of functional prothymocytes in the rat reflects major differences in the representation 
of prothymocytes in these species. Roughly equivalent numbers of bone marrow and 
spleen cells, when normalized for body weight, are required to regenerate thymocytes 
in mice and rats; and the kinetics of regeneration and the threshold of irradiation are 
identical in both species (5, 30).1 Moreover, above a critical dose of irradiation  (~400 
rad),  the  thymocyte  regeneration  assays  in  both  mice  and  rats  are  strictly  dose- 
dependent. Therefore, it is unlikely that the small number of detectable prothymocytes 
in rat bone marrow is a  unique consequence of our assay system. 
Although additional experiments will be required to resolve the preceding issues, it 
is tempting to speculate on the identity of the prothymocytes that we have enriched 
on  the  FACS.  It  seems safe to  conclude  that,  at  a  minimum,  the  dexamethasone- 
sensitive prothymocytes are not  CFU-S,  almost  all  of which  are cortisone-resistant 
(15).  A  priori  reasoning  would  suggest,  instead,  that  the  dexamethasone-sensitive 
prothymocyte subset in bone marrow is composed of TdT-positive cells. Thus, in the 
mouse, the majority of TdT-positive bone marrow cells can be induced to express T 
cell differentiation antigens, and the majority of inducible bone marow cells are TdT- 
positive (9). Moreover, most cortical thymocytes are also TdT-positive, but medullary 
thymocytes and peripheral T  cells are TdT negative (31,  32). However, there was no 1458  IDENTIFICATION  OF THYMOCYTE PROGENITORS 
correlation in the present study between the enrichment of TdT-positive bone marrow 
cells  and  the  enrichment  of prothymocytes. Indeed,  75%  of the  total  TdT-positive 
cells were excluded from the prothymocyte-rich fraction. Furthermore, a  population 
of dexamethasone-sensitive  prothymocytes was  also  identified  in  adult  rat  spleen, 
which lacks TdT-positive cells. None of this excludes the possibility that TdT-positive 
bone marrow cells  may function as  prothymocytes in  the  intact  host.  It  is  equally 
possible that, for technical reasons, TdT-positive bone marrow cells  cannot function 
as prothymocytes in our adoptive transfer assay system or that only a minor subset of 
TdT-positive cells  can function as prothymocytes at any particular time.  Moreover, 
although TdT-positive cells  are  not  normally present  in  adult  spleen,  it  should  be 
noted that many prethymic cells in spleen can be rapidly induced to express TdT (9). 
The identity of the dexamethasone-resistant prothymocyte subset is also problem- 
atic, especially because it coisolates with CFU-S on the FACS (15).  However, there is 
considerable evidence from other studies  that  functional prothymocytes are distinct 
from  CFU-S,  and  that  they  constitute  a  developmentally  and  physically  discrete 
population of actively proliferating cells  in hemopoietic tissues  (6-8, 25, 33). 
In studies  in progress, we demonstrated that  the dexamethasone-resistant  prothy- 
mocytes can generate TdT-positive thymocytes in vivo, thereby suggesting that they 
belong to the committed subset of pre-TdT-positive cells  (9). In addition, we recently 
used a selective culture system (34) to generate TdT-positive rat bone marrow cells in 
vitro. We found that the bone marrow cell fraction that is enriched for dexamethasone- 
resistant  prothymocytes is comparably enriched for cells  that can generate undiffer- 
entiated TdT-positive cells  in vitro (unpublished observations). The growth kinetics 
of these TdT-positive cells  suggest that  they are derived from actively proliferating 
precursors,  which,  therefore,  are  unlikely  to  be  CFU-S.  Our working hypothesis is 
that the in vivo precursors of thymocytes and the in vitro precursors of TdT-positive 
cells  belong to  a  common pool  of dexamethasone-resistant  prothymocytes. We  are 
presently  attempting  to  further  characterize  this  highly  enriched  population  of 
prothymocytes and to physically separate it  from CFU-S. We are also attempting to 
determine  whether TdT-positive cells  and  other undifferentiated  cells  that  can  be 
induced to express T  cell  markers can function as prothymocytes in other thymocyte 
regeneration assays. For the moment, however, the objective evidence is that functional 
prothymocytes constitute  a  much  smaller  subset  of bone  marrow  cells  than  had 
heretofore been suspected. 
Summary 
A  quantitative thymocyte regeneration assay was used to monitor the isolation of 
functional prothymocytes from rat  bone marrow on the FACS. Two prothymocyte 
subpopulations were tentatively identified on the basis of their relative resistance to 
dexamethasone.  Both populations were comprised of undifferentiated,  medium-size 
cells  that  displayed large amounts of Thy-1  antigen.  Simultaneous  sorting of bone 
marrow cells  according to relative low angle light scatter  (size) and relative fluores- 
cence intensity for Thy-1 resulted in enrichments of 112-fold and 260-fold, respectively, 
in  prothymocyte activity  in  untreated  and  dexamethasone-treated  bone  marrow. 
These prothymocyte-enriched cell  fractions contained ~75% of total functional pro- 
thymocyte activity in bone marrow, and represented  1.1 and 0.35% of total untreated 
and  dexamethasone-treated  bone marrow cells.  Using these  enriched  cell  fractions, D.  L.  GREINER,  I. GOLDSCHNEIDER,  AND  R.  W.  BARTON  1459 
significant thymocyte regeneration is possible with as few as 2 ×  104 and 1 ×  104 bone 
marrow cells, respectively. The possible relationship of these functional prothymocyte 
subpopulations with CFU-S and with TdT-positive cells is discussed. 
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